Advances in Gastric and GE Junction Cancer Treatment: Durvalumab Combined with FLOT Shows Promising Results at ASCO
A groundbreaking phase 3 trial shows that combining durvalumab with FLOT chemotherapy significantly improves outcomes for patients with resectable gastric and GE junction cancer, offering new hope in cancer treatment.
Recent research presented at the American Society of Clinical Oncology (ASCO) meeting highlights a significant breakthrough in the treatment of resectable gastric and gastroesophageal (GE) junction adenocarcinoma. A phase 3, double-blind clinical trial investigated the efficacy of adding durvalumab, an immunotherapy drug, to the standard FLOT chemotherapy regimen.
The study involved 948 patients who were randomly assigned to receive either durvalumab (1,500 mg) or a placebo every four weeks. The treatment plan included four cycles of the combined therapy followed by 10 additional cycles of durvalumab or placebo. The primary focus was to assess event-free survival, which measures the length of time patients remain free from disease progression or recurrence.
Findings demonstrated that patients receiving durvalumab experienced notably better outcomes. The two-year event-free survival rate was 67.4% in the durvalumab group compared to 58.5% in the placebo group. Overall survival also improved, with 75.7% of durvalumab-treated patients surviving at two years versus 70.4% in the control group. Additionally, a higher proportion of patients in the durvalumab group achieved a pathological complete response (19.2% vs. 7.2%), indicating an absence of detectable cancer after treatment.
Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center emphasized the importance of these findings, stating that this therapy combination could represent a major advancement for patients facing this challenging diagnosis. The results suggest that adding durvalumab to the FLOT regimen could significantly enhance patient outcomes, bringing hope for higher cure rates.
The study was sponsored by AstraZeneca, which manufactures durvalumab. Several authors disclosed ties to pharmaceutical companies, aligned with the industry-led nature of the research.
For more on this study, visit the published article in the New England Journal of Medicine and the ASCO annual meeting resources.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Algorithm Enhances Fitness Tracking for People with Obesity
A new open-source algorithm developed by Northwestern University enhances the accuracy of fitness trackers for people with obesity, improving health monitoring and personalized interventions.
Expert Insights on Brain Health and the Significance of Prop 14
Rice University experts highlight how fundamental chemistry research is vital for understanding and treating neurodegenerative diseases, with Prop 14 poised to boost brain health initiatives in Texas.
Hidden Dangers of Vaping: Harmful Substances Emitted by E-Cigarettes Under Scrutiny
Emerging research reveals that e-cigarettes emit toxic metals and particles, posing health risks for users and bystanders. Discover the latest findings on vaping safety and chemical emissions.
Early Colonoscopy Screening at Age 45 Shows Similar Neoplasia Detection Rates as Older Adults, Supporting New Guidelines
New research supports lowering the age for colonoscopy screenings to 45, showing detection rates similar to older adults and bolstering updated guidelines for colorectal cancer prevention.